Published in Psychopharmacology (Berl) on January 01, 1993
Animal models of schizophrenia. Br J Pharmacol (2011) 1.60
The "two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment. Psychopharmacology (Berl) (2003) 1.49
Glutaminase-deficient mice display hippocampal hypoactivity, insensitivity to pro-psychotic drugs and potentiated latent inhibition: relevance to schizophrenia. Neuropsychopharmacology (2009) 1.20
Modulators of the glycine site on NMDA receptors, D-serine and ALX 5407, display similar beneficial effects to clozapine in mouse models of schizophrenia. Psychopharmacology (Berl) (2005) 1.18
Genetic and pharmacological evidence for schizophrenia-related Disc1 interaction with GSK-3. Synapse (2011) 0.99
Sex-dependent antipsychotic capacity of 17β-estradiol in the latent inhibition model: a typical antipsychotic drug in both sexes, atypical antipsychotic drug in males. Neuropsychopharmacology (2010) 0.84
A new model of the disrupted latent inhibition in C57BL/6J mice after bupropion treatment. Psychopharmacology (Berl) (2009) 0.80
The antipsychotic drug, fluphenazine, effectively reverses mechanical allodynia in rat models of neuropathic pain. Psychopharmacology (Berl) (2007) 0.79
A rat model of distractibility: effects of drugs modifying dopaminergic, noradrenergic and GABAergic neurotransmission. J Neural Transm (Vienna) (1997) 0.77
The latent inhibition model of schizophrenic attention disorder and of antipsychotic drug action: comment on Dunn, Atwater and Kilts (Psychopharmacology, 1993, 112:315-323) Psychopharmacology (Berl) (1994) 0.77
Involvement of D1 and D2 dopamine receptor in the retrieval processes in latent inhibition. Psychopharmacology (Berl) (2015) 0.76
Deficits in latent inhibition induced by estradiol replacement are ameliorated by haloperidol treatment. Front Behav Neurosci (2013) 0.76
Enhancement of latent inhibition by two 5-HT2A receptor antagonists only when given at both pre-exposure and conditioning. Psychopharmacology (Berl) (2002) 0.76
Paradoxical effects of low dose MDMA on latent inhibition in the rat. Neuropharmacology (2012) 0.75
Amygdala activity related to enhanced memory for pleasant and aversive stimuli. Nat Neurosci (1999) 3.33
Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science (1984) 2.83
Comparison of dopamine uptake in the basolateral amygdaloid nucleus, caudate-putamen, and nucleus accumbens of the rat. J Neurochem (1995) 1.62
Sertraline and desmethylsertraline in human breast milk and nursing infants. Am J Psychiatry (1997) 1.62
Alterations in the functional anatomy of working memory in adult attention deficit hyperactivity disorder. Am J Psychiatry (2000) 1.45
Alterations in corticotropin-releasing factor-like immunoreactivity in discrete rat brain regions after acute and chronic stress. J Neurosci (1986) 1.30
Effects of acute and chronic 1,3-butanediol treatment on central nervous system function: a comparison with ethanol. J Pharmacol Exp Ther (1981) 1.26
18F-labeled FECNT: a selective radioligand for PET imaging of brain dopamine transporters. Nucl Med Biol (2000) 1.21
Neural correlates of maternal separation in rhesus monkeys. Biol Psychiatry (2001) 1.08
Differential functional connectivity within an emotion regulation neural network among individuals resilient and susceptible to the depressogenic effects of early life stress. Psychol Med (2012) 1.08
Topographic nonoverlapping distribution of D1 and D2 dopamine receptors in the amygdaloid nuclear complex of the rat brain. Synapse (1992) 1.03
Synthesis and characterization of fluorinated and iodinated pyrrolopyrimidines as PET/SPECT ligands for the CRF1 receptor. Nucl Med Biol (2001) 0.96
Quantitation of plasma catecholamines by on-line trace enrichment high performance liquid chromatography with electrochemical detection. J Neurosci Methods (1984) 0.96
Simultaneous quantification of dopamine, 5-hydroxytryptamine and four metabolically related compounds by means of reversed-phase high-performance liquid chromatography with electrochemical detection. J Chromatogr (1981) 0.95
Synthesis and pharmacology of hydroxylated metabolites of methylphenidate. J Med Chem (1981) 0.94
Selective activation of mesoamygdaloid dopamine neurons by conditioned stress: attenuation by diazepam. Brain Res (1992) 0.92
Alteration of cerebral neurotransmitter receptor function by exposure of rats to manganese. Toxicol Lett (1981) 0.92
Corticotropin-releasing factor-like immunoreactivity in senile dementia of the Alzheimer type. Reduced cortical and striatal concentrations. JAMA (1985) 0.91
Gas chromatographic-mass spectrometric analysis of methylphenidate and p-hydroxymethylphenidate using deuterated internal standards. J Chromatogr (1985) 0.90
Potential corticotropin-releasing factor pathways in the rat brain as determined by bilateral electrolytic lesions of the central amygdaloid nucleus and the paraventricular nucleus of the hypothalamus. J Neuroendocrinol (1993) 0.89
Enhanced neurotensin neurotransmission is involved in the clinically relevant behavioral effects of antipsychotic drugs: evidence from animal models of sensorimotor gating. J Neurosci (2001) 0.88
Clinical milestones predict symptom remission over 6-month and choice of treatment of patients with major depressive disorder (MDD). J Psychiatr Res (2008) 0.87
Quantification of R-(+)-7-chloro-8-hydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-methyl-3- benzazepine in brain and blood by use of reversed-phase high-performance liquid chromatography with electrochemical detection. J Chromatogr (1985) 0.86
Multiple forms of the D1 dopamine receptor: its linkage to adenylate cyclase and psychopharmacological effects. Psychopharmacol Bull (1986) 0.84
Functional brain imaging: twenty-first century phrenology or psychobiological advance for the millennium? Am J Psychiatry (1999) 0.83
Susceptibility and resistance of rats to stress-induced decreases in swim-test activity: a selective breeding study. Brain Res (1996) 0.83
Neural activity related to anger in cocaine-dependent men: a possible link to violence and relapse. Am J Addict (2000) 0.83
Erythrosine (Red No. 3) and its nonspecific biochemical actions: what relation to behavioral changes? Science (1980) 0.82
Biodistribution and radiation dosimetry of the dopamine transporter ligand. J Nucl Med (2001) 0.82
Anatomy and mechanisms of neurotensin-dopamine interactions in the central nervous system. Ann N Y Acad Sci (1995) 0.81
The multiplicity of the D1 dopamine receptor. Adv Exp Med Biol (1986) 0.81
Effects of thioridazine and its metabolites on dopaminergic function: drug metabolism as a determinant of the antidopaminergic actions of thioridazine. J Pharmacol Exp Ther (1984) 0.79
Neurotensin induces Fos and Zif268 expression in limbic nuclei of the rat brain. Neuroscience (1996) 0.79
CSF monoamine metabolites in chronic pain. Pain (1987) 0.79
Evidence for a tonic facilitatory influence of substance P on dopamine release in the nucleus accumbens. Brain Res (1986) 0.78
Behavioral and biochemical studies of the scopolamine-induced reversal of neuroleptic activity. Psychopharmacology (Berl) (1981) 0.78
Platelet MAO activity in posttraumatic stress disorder. Am J Psychiatry (1985) 0.78
Mesoamygdaloid dopamine neurons: differential rates of dopamine turnover in discrete amygdaloid nuclei of the rat brain. Brain Res (1987) 0.78
Haloperidol enhancement of latent inhibition: relation to therapeutic action? Biol Psychiatry (1988) 0.78
Increase in dopamine metabolites in rat brain by neurotensin. J Pharmacol Exp Ther (1982) 0.77
Serum concentrations of thioridazine, its major metabolites and serum neuroleptic-like activities in schizophrenics with and without tardive dyskinesia. Acta Psychiatr Scand (1982) 0.76
Uptake of serotonin into rat platelets and synaptosomes: comparative structure-activity relationships, energetics and evaluation of the effects of acute and chronic nortriptyline administration. Brain Res Bull (1986) 0.76
Comparison of anti-conflict drug effects in three experimental animal models of anxiety. Psychopharmacology (Berl) (1981) 0.76
Accuracy of surface fit registration for PET and MR brain images using full and incomplete brain surfaces. J Comput Assist Tomogr (1995) 0.75
Mass fragmentographic determination of 3, 4 dihydroxyphenylethylamine and 4-hydrox-3-methoxyphenylethylamine in the caudate nucleus. J Neurochem (1977) 0.75
Analytical considerations for quantitative determination of serotonin and its metabolically related products in biological matrices. Clin Chem (1985) 0.75
Lack of central 5-hydroxytryptamine influence on the anticonflict activity of diazepam. Psychopharmacology (Berl) (1982) 0.75
A commentary on methods in peptide neurobiology: focus on neurotensin. Crit Rev Neurobiol (1992) 0.75
Radioligands for PET and SPECT Imaging of the central noradrenergic system. CNS Spectr (2001) 0.75
Aminergic studies and cerebrospinal fluid cations in suicide. Ann N Y Acad Sci (1986) 0.75
Quantitative determination of 5-hydroxytryptophan in dissected brain regions by on-line trace enrichment HPLC with electrochemical detection. Life Sci (1984) 0.75
Animal models related to developmental disorders: theoretical and pharmacological analyses. Appl Res Ment Retard (1981) 0.75
Chronic lithium treatment decreases neuronal activity in the nucleus accumbens and cingulate cortex of the rat. Neuropsychopharmacology (1999) 0.75
The effect of the stereoisomers of butaclamol on neurotensin content in discrete regions of the rat brain. Neuropsychopharmacology (1988) 0.75
Effects of the isomers of N-n-propylnorapomorphine and haloperidol on regional concentrations of neurotensin in rat brain. Neuropsychopharmacology (1991) 0.75
N-oxides of phenothiazine antipsychotics: effects on in vivo and in vitro estimates of dopaminergic function. J Pharmacol Exp Ther (1983) 0.75
Endogenous dopamine and serotonin release from the explanted rat tuberohypophyseal system: effects of electrical stimulation and neurotensin. Life Sci (1987) 0.75
Simultaneous determination of thioridazine and its S-oxidized and N-demethylated metabolites using high-performance liquid-chromatography on radially compressed silica. J Chromatogr (1982) 0.75
Schistosoma mansoni: tyrosine, a putative in vivo substrate of phenol oxidase. Exp Parasitol (1980) 0.75
Thioridazine and the neuroleptic radioreceptor assay. Biol Psychiatry (1984) 0.75